Four recent FDA Warning Letters involving sales of US domestic peptides:
Xcel Peptides -
Xcel Research LLC - 694608 - 12/10/2024
Prime Peptides -
Prime Vitality, Inc. dba Prime Peptides - 695156 - 12/10/2024
Summit Peptides -
Summit Research Peptides - 695607 - 12/10/2024
SwissChems -
Swisschems - 695663 - 12/10/2024
(SwissChems has been an established vendor - though always with mixed, sketchy reviews - for nootropics, SARMS, and Research Chemicals for many years.)
This set of FDA Warning Letters seems to involve:
1. The classic mistake where vendors include any language that indicates products may be sold for human use.
(For example, product descriptions & product labels with statements about health benefits, medical use cases, dose size/schedule, how to administer.)
2. Attention on peptide product keywords. In these cases, "SEMAGLUTIDE", "TIRZEPATIDE", "RETATRUTIDE", "TESAMORELIN", and other generic, non-branded peptide names.